Psyence Biomedical Ltd. (NasdaqCM: PBM)
Health Care · Biotechnology · CA
$4.22
-15.09% today · -80.3% 1Y
Psyence Biomedical Ltd. (NasdaqCM: PBM) operates in the Biotechnology industry within the Health Care sector. The company is valued at $16.10M and employs 12 people.
Over the last twelve months the share price has lost 80.3%, trading between 1.92 and 22.25.
Tweenvest scores Psyence Biomedical Ltd. across four factors: quality 37/100, value 50/100. Its strongest factor is value.
PBM price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $16.10M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -12.56
- Dividend yield
- —
- Beta (5Y)
- 1.69
- 52-week high
- $22.25
- 52-week low
- $1.92
- Avg volume (3M)
- —
- Shares outstanding
- 3.81M
- Employees
- 12
- Next earnings
- —
About Psyence Biomedical Ltd.
Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care. Its leading investigational drug, PEX010, a capsule made with naturally sourced psilocybin, is currently in a Phase IIb clinical study. This product is being developed to treat anxiety, depression, and associated conditions such as post-traumatic stress disorder (PTSD), stress, grief, and adjustment disorder, especially in a palliative care context. Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010, utilizing psilocybin-assisted psychotherapy for adjustment disorder arising from incurable cancer. Additionally, the company holds a strategic alliance with PsyLabs for the manufacturing of Ibogaine. Headquartered in Toronto, Canada, Psyence Biomedical Ltd. functions as a subsidiary of Psyence Group Inc.
- ISIN
- CA74449F4078
- Listed since
- Dec 10, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Shaperon Inc.KOSDAQ: A378800 | $16.44M | ₩2,370.00 | -11.57% |
| Bioray Biotech Co., LtdTPEX: 7561 | $16.41M | NT$18.00 | -3.23% |
| Biotechnology Assets, S.A.BME: BST | $16.39M | €0.20 | +6.85% |
| aTyr Pharma, Inc.NasdaqCM: ATYR | $16.19M | $0.17 | -2.88% |
| TScan Therapeutics, Inc.NasdaqGM: TCRX | $15.66M | $0.23 | -2.94% |
| Onco-Innovations LimitedCNSX: ONCO | $15.60M | CA$0.32 | -13.51% |
| Xcell Therapeutics Inc.KOSDAQ: A373110 | $15.16M | ₩1,169.00 | +9.87% |
| Read-Gene S.A.WSE: RDG | $15.06M | zł4.96 | -1.59% |
Figures last refreshed Oct 18, 2026.